Transdermal buprenorphine in children with cancer-related pain

Pediatric Blood and Cancer

Volumn 52, Issue 1, 2009, Pages 125-127

  Attinà, Giorgio ^a   Ruggiero, Antonio ^a   Maurizi, Palma ^a   Arlotta, Annalisa ^a   Chiaretti, Antonio ^a   Riccardi, Riccardo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Buprenorphine; Cancer pain; Children; Transdermal patch

Indexed keywords

ANALGESIC AGENT; ANTINEOPLASTIC AGENT; BUPRENORPHINE; FENTANYL CITRATE; GABAPENTIN; IBUPROFEN; OPIATE; PARACETAMOL; TRAMADOL; NARCOTIC ANALGESIC AGENT;

ABDUCENS NERVE PARALYSIS; AGED; ANALGESIA; ANAMNESIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER PAIN; CANCER PATIENT; CASE REPORT; CHILD; CHILDHOOD CANCER; CLINICAL EVALUATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; ERYTHEMA; HUMAN; LYMPHOCYTIC INFILTRATION; MALE; NEUROFIBROMATOSIS; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PRURITUS; RHABDOMYOSARCOMA; SKIN MANIFESTATION; SLEEP; STATISTICAL SIGNIFICANCE; VISUAL ANALOG SCALE; INTRADERMAL DRUG ADMINISTRATION; NEOPLASM; PAIN; PATHOLOGY;

ADMINISTRATION, CUTANEOUS; ANALGESICS, OPIOID; BUPRENORPHINE; CHILD, PRESCHOOL; HUMANS; MALE; NEOPLASMS; PAIN;

EID: 58149389161     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21736     Document Type: Article

References (19)

1. Mercadante S. Cancer pain management in children. Palliat Med 2004;18:654-662.
2. Miaskowski C, Cleary J, Burney R, et al. Guideline for the management of cancer pain in adults and children. Glenview, IL: American Pain Society (APS) 2005. 166 p. Clinical practice guideline; no. 3.
3. Thomas BJ, Finnin BC. The transdermal revolution. Drug Discov Today 2004;9:697-703.
4. Skaer TL. Practice guidelines for transdermal opioids in malignant pain. Drugs 2004;64:2629-2638.
5. Griessinger N, Sittl R, Likar R. Transdermal buprenorphine in clinical practice-a post-marketing surveillance study in 13,179 patients. Curr Med Res Opin 2005;21:1147-1156.
6. Bohme K. Buprenorphine in a transdermal therapeutic system - A new option. Clin Rheumatol 2002;21:S13-S16.
7. Michel E, Zernikow B. Buprenorphine in children. A clinical and pharmacological review. Schmerz 2006;20:40-50.
8. Likar R, Kayser H, Sittl R. Long-term management of chronic pain with transdermal buprenorphine: A multicenter, open-label, follow-up study in patients from three short-term clinical trials. Clin Ther 2006;28:943-952.
9. Sittl R. Transdermal buprenorphine in cancer pain and palliative care. Palliat Med 2006;20:S25-S30.
10. Radbruch L. Buprenorphine TDS: Use in daily practice, benefits for patients. Int J Clin Pract Suppl 2003;133:19-22.
11. Zernikow B, Smale H, Michel E, et al. Paediatric cancer pain management using the WHO analgesic ladder-results of a prospective analysis from 2265 treatment days during a quality improvement study. Eur J Pain 2006;10:587-595.
12. Sittl R. Buprenorphine transdermal patch: Clinical expert report. Germany: Grunenthal GmbH; 2000.
13. Mercadante S, Ferrera P, Villari P. Is there a ceiling effect of transdermal buprenorphine? Preliminary data in cancer patients. Support Care Cancer 2007;15:441-444.
14. Sorge J, Sittl R. Transdermal buprenorphine in the treatment of chronic pain: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 2004;26:1808-1820.
15. Payne R, Mathias SD, Pasta DJ, et al. Quality of life and cancer pain: Satisfaction and side effects with transdermal fentanyl versus oral morphine. J Clin Oncol 1998;16:1588-1593.
16. Pereira J, Lawlor P, Vigano A, et al. Equianalgesic dose ratios for opioids: A critical review and proposals for long-term dosing. J Pain Sympt Manage 2001;22:672-687.
17. Sittl R, Likar R, Nautrup BP. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: Results of a retrospective cohort study. Clin Ther 2005;27:225-237.
18. Bieri D, Reeve RA, Champion GD, et al. The Faces Pain Scale for the self-assessment of the severity of pain experienced by children: Development, initial validation, and preliminary investigation for ratio scale properties. Pain 1990;41:139-150.
19. Schmid-Grendelmeier P, Pokorny R, Gasser UE, et al. A comparison of the skin irritation potential of transdermal fentanyl versus transdermal buprenorphine in middle-aged to elderly healthy volunteers. Curr Med Res Opin 2006;22:501-509.